An activity score does not replace visual-function assessment, and steroid response does not prove an idiopathic cause.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Recognise thyroid eye disease and its risks
Thyroid eye disease (TED), Graves orbitopathy or endocrine orbitopathy is a common cause of adult unilateral or bilateral, often asymmetric proptosis. Usually associated with Graves hyperthyroidism, it can occur with hypothyroidism or euthyroidism. The original proportions—94% thyroid dysfunction, 6% euthyroid, 90% Graves among those with dysfunction and 30% clinical TED among Graves patients—describe different denominators and are not universal contemporary prevalence estimates. 1
Women are affected more often, commonly in the 5th–7th decades; men may present later, after 50 years, with more severe disease. Smoking is an important modifiable risk. The export’s sevenfold risk increase depends on population and endpoint and must not be used as an individual prediction. Explain cessation support and stable thyroid control without blaming patients. 1
Immune activation expands orbital muscle and connective/fat tissue through inflammation, fluid and glycosaminoglycan accumulation. The original eightfold muscle enlargement is an illustrative extreme, not a diagnostic threshold. Apical crowding can compress the optic nerve; later fibrosis causes restrictive motility and diplopia. Appearance, discomfort and psychosocial burden matter alongside sight. 1
02Assess visual function and confirm the pattern
Pain or morning pressure, photophobia, dryness, reduced vision, diplopia and altered appearance prompt assessment. Measure acuity, pupils, colour vision, fields, corneal exposure, motility, proptosis and soft-tissue changes. Compressive dysthyroid optic neuropathy is an emergency and may occur without dramatic proptosis or a high activity score; disc swelling is not obligatory. The sign table retains all original clinical domains. 1
Check thyroid history, T3, T4, TSH and appropriate antibodies such as TSH-receptor antibodies. Hormone levels do not directly grade orbital activity or severity. The export’s two-of-three rule (thyroid dysfunction, clinical signs, imaging) is a teaching framework, not a universal validated diagnostic criterion; atypical, unilateral or euthyroid cases need careful differential diagnosis. 1
CT or MRI can show fusiform muscle-belly enlargement with relative tendon sparing, the Coca-Cola sign. Inferior, medial, superior and lateral rectus involvement is a common teaching sequence, not an obligatory order. Imaging assesses apical crowding, alternatives and decompression planning; contrast use depends on the clinical question. Biopsy is uncommon in typical TED but may be needed when lymphoma or another inflammatory process is suspected. Pretibial myxoedema or acropachy suggests substantial systemic autoimmunity, not a stand-alone orbital prognosis test. 1
| Sign | Meaning and action |
|---|---|
| Lid retraction | Common upper/lower lid sign; lateral flare can be prominent. Assess closure and exposure. |
| Von Graefe sign | Upper lid lags in downgaze; supports pattern but does not establish activity alone. |
| Proptosis | Unilateral/bilateral and often asymmetric; exposure can ulcerate the cornea. Severe secondary infection including endophthalmitis is a possible complication, not typical uncomplicated TED. |
| Restrictive myopathy | Fibrosis often affects inferior rectus, limiting elevation with hypotropia and diplopia; examine all movements. |
| Compressive optic neuropathy | Emergency: acuity, colour or field loss, sometimes inferior paracentral defects; pupils and disc may be abnormal, but swelling need not occur. Urgent repeated functional assessment and treatment. |
| Soft tissues | Conjunctival/periorbital redness and oedema, chemosis and redness over horizontal rectus insertions; distinguish congestion, exposure and other causes. |
03Distinguish activity from severity
The Rundle curve describes an active inflammatory phase, plateau and later quieter fibrotic phase; the export says activity may last up to 3 years. Individual duration varies and relapse is possible. Residual restriction and appearance changes may persist. NOSPECS describes severity historically; VISA considers Vision, Inflammation, Strabismus and Appearance. None replaces repeated visual-function assessment. 1
CAS assigns 1 point each for spontaneous retrobulbar pain, pain on eye movement, lid redness, lid swelling, conjunctival redness, chemosis and inflamed/swollen caruncle or plica: 7 baseline items. A score ≥3/7 supports activity. Use consistent definitions and examination rather than assigning points to any redness from any cause. 1
Follow-up adds progression items: proptosis increase ≥2 mm, acuity reduction ≥1 line and movement reduction ≥8 degrees, making 10 items; ≥4/10 is the export’s active follow-up threshold. Specify the observation interval and standardized measurement. CAS alone neither mandates immunosuppression nor excludes optic neuropathy: severity, progression, duration and patient impact determine treatment. 1
04Select medical treatment by indication
Offer smoking cessation, lubrication, sunglasses, head elevation and selected prisms or occlusion for diplopia. The export mentions low salt and 2–3 pillows as comfort measures, not disease-modifying substitutes. Selenium for 6 months may be considered in mild active TED, particularly selenium-deficient regions; avoid indiscriminate supplementation or assuming benefit in every patient. Coordinate thyroid control with endocrinology. 1 2 3
Radioiodine can worsen orbitopathy in at-risk patients; select thyroid treatment and glucocorticoid prophylaxis according to activity and risk. The export’s prednisolone 0.5 mg/kg is not an automatic dose for all TED or all radioiodine recipients. Prescribing requires the complete regimen, contraindications and current local guidance. 1 2
For active moderate-to-severe disease, distinguish planned weekly therapy from optic-neuropathy rescue. The export’s 0.5–1.0 g IV methylprednisolone weekly for 6–12 weeks is not a single safe general regimen. Guidance commonly uses 0.5 g weekly for 6 weeks then 0.25 g for 6 weeks, total 4.5 g; EUGOGO recommends combination with mycophenolate in suitable patients. Treatment requires hepatic, cardiovascular, infection and metabolic risk assessment and monitoring; repeated high doses cannot be extrapolated freely. 1 2 3
Sight-threatening optic neuropathy needs urgent specialist IV glucocorticoids and close response assessment, with early decompression when recovery is inadequate; do not wait for completion of a weekly course or an inactive phase. The original oral prednisolone 1 mg/kg is a contextual option, not equivalent rescue treatment. Gastroprotection when indicated, bone-risk reduction, glucose and liver monitoring belong in the individual systemic-steroid plan. 1 3
Teprotumumab can reduce proptosis and inflammation; it is not guaranteed nonsurgical decompression. EMA now authorises Tepezza for adults with moderate-to-severe TED, superseding older statements of European nonavailability. Hearing impairment, hyperglycaemia, infusion reactions, inflammatory bowel disease and fetal harm require screening and counselling; pregnancy is contraindicated. Access and cost remain jurisdiction-specific. Rituximab, tocilizumab, mycophenolate or methotrexate are selected specialist options with different evidence and risks, not interchangeable medicines. 1 4
Orbital radiotherapy is a selected option, often combined with glucocorticoids, particularly for motility-related active disease. Its response is slower than immediate steroid rescue; the export’s claim of greater durability is not a universal comparative result. Assess contraindications and radiation risks; it is not a substitute for urgent treatment of deteriorating vision. 1 2 3
05Stage rehabilitation after stability
Elective rehabilitation generally follows stable inactive disease and controlled thyroid function. The export suggests 6–9 months of inactivity; use procedure-specific stability assessment rather than one rigid interval. The usual DSL sequence is decompression, strabismus and eyelids. Emergency decompression for neuropathy or severe exposure is the exception and must not wait for elective stability. 1
Decompression removes fat and/or medial, lateral or inferior bone according to indication, anatomy and goals. Balanced medial/lateral decompression can limit some displacement risks but does not abolish new diplopia or other complications. Strabismus surgery usually recesses restricted muscles; the export’s never resect rule is too absolute. Lid retractor recession or selected spacers address retraction after earlier stages; levator botulinum toxin may be a temporary specialist option. Not every patient needs every stage. 1 3
06Investigate other systemic orbital disease
Granulomatosis with polyangiitis (GPA, formerly Wegener) is necrotizing granulomatous vasculitis that can involve the orbit, sometimes from adjacent sinuses. The export’s approximately 50% refers to an unresolved involvement denominator and should not be taught as universal orbital prevalence. PR3/c-ANCA supports a compatible diagnosis but a negative test does not exclude localized disease. Biopsy may show vasculitis, granulomas and necrosis, not necessarily the complete triad. Organ-threatening disease needs systemic specialist therapy; cyclophosphamide and glucocorticoids are original examples, not the only current choices. 1
Sarcoidosis may cause palpable bilateral lacrimal enlargement and noncaseating granulomas. Imaging, systemic assessment and selected biopsy establish a compatible diagnosis while excluding mimics such as infection or lymphoma. Serum ACE is supportive at most and neither proves nor excludes sarcoidosis alone. 1
IgG4-related disease is systemic fibroinflammation that can enlarge lacrimal glands, infraorbital/trigeminal nerves and extraocular muscles. Serum IgG4 elevation is insufficient alone. Biopsy interpretation combines lymphoplasmacytic infiltrates, cell counts and IgG4/IgG ratio with the organ pattern; the original >40% ratio alone is not highly diagnostic. Storiform fibrosis and obliterative phlebitis may be absent in orbital tissue. Exclude lymphoma, which can also contain IgG4-positive cells, and assess systemic disease. Glucocorticoids or rituximab may be used; relapse is common. 1 5
07Exclude mimics before calling inflammation idiopathic
Nonspecific/idiopathic orbital inflammation (NSOI/IOI, historical orbital pseudotumour) is a diagnosis of exclusion. Acute unilateral pain and swelling can resemble orbital cellulitis; absence of fever does not exclude infection. Myositis may involve muscle tendons, unlike typical TED, but tendon involvement is not an absolute separator and lateral-rectus-first is not obligatory. Dacryoadenitis involves the lacrimal gland; painful ophthalmoplegia at the apex/cavernous sinus also raises Tolosa-Hunt and dangerous infectious, vascular or neoplastic alternatives. 1
CT/MRI defines distribution and infiltrative change. Tissue diagnosis is particularly important for nonmyositic masses, atypical or recurrent disease and suspected lymphoma; plan biopsy timing before steroids when safe because treatment can obscure histology. The export’s dramatic response within 24–48 hours is supportive only, not proof of idiopathic disease. Refractory or fibrosing disease may need additional immunomodulation or radiotherapy after reassessment. 1 6
Coordinate ophthalmic/orbital surgery, endocrinology, radiology, rheumatology and pathology through multidisciplinary review. Revisit diagnosis when the clinical course, imaging, histology or treatment response fails to fit; shared review is particularly important before prolonged immunosuppression or irreversible surgery. 1
What are the main learning points?
Separate TED activity and severity, detect optic neuropathy, individualise medicine and staged surgery, and exclude systemic disease, infection and neoplasia before diagnosing IOI.
Which findings require urgent assessment?
Rapid visual loss, severe pain, marked inflammation, pressure rise, suspected infection or neurological disease; colour/field loss and corneal breakdown are especially concerning in orbital disease.
References and access status
- 1Immutable original orbital-inflammation export
Original read; lecture recording and unreferenced numerical assertions unverified.
- 2EUGOGO clinical practice guidelines (2021)
Indexed recommendations and regimen excerpts inspected; direct publisher open failed; whole guideline and supplements not read.
- 3ATA/ETA consensus on thyroid eye disease (2022)
Selected key points and sections on dosing, selenium, surgery and optic neuropathy read; whole text/supplements not appraised.
- 4EMA: Tepezza overview and indication
Official overview/indication and risk passages read; complete product information not appraised.
- 52023 revised diagnostic criteria for IgG4-related ophthalmic disease (2024)
Indexed organ-specific criteria table and selected discussion inspected; not entire article.
- 6Consensus on diagnostic criteria of idiopathic orbital inflammation (2017)
Abstract and indexed selected primary consensus text inspected; validation limitations remain.
Original lecture link
For patients
Thyroid eye disease can cause swelling, bulging, dryness and double vision even when thyroid hormone tests are normal.
Eye and thyroid specialists choose treatment from activity, severity and individual risks. Stop smoking and follow prescribed surface care; do not take steroids or selenium on your own. This text does not replace examination.
Seek immediate help for reduced vision or colour perception, new field loss, severe pain, inability to close the eye or a damaged cornea.
New acuity or colour loss, field defects, severe exposure, corneal ulceration or suspected orbital infection require immediate specialist assessment.